Oncology - Lung
Perspective | New lung cancer screening guideline comes with many caveats
14 Mar, 2021 | 20:23h | UTCNew lung cancer screening guideline comes with many caveats – Lown Institute
Original Guideline: USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk (article and commentaries)
USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk
10 Mar, 2021 | 08:28h | UTCRecommendation Statement: Screening for Lung Cancer – US Preventive Services Task Force
Editorials: Broadened Eligibility for Lung Cancer Screening: Challenges and Uncertainty for Implementation and Equity – JAMA AND Expanded Access to Lung Cancer Screening—Implementing Wisely to Optimize Health – JAMA Network Open AND New USPSTF Guidelines for Lung Cancer Screening: Better but Not Enough – JAMA Surgery AND The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening: The More Things Stay the Same… – JAMA Oncology
Five-year outcomes from randomized, phase III trials: Nivolumab vs. Docetaxel in previously treated non–small-cell lung cancer
3 Mar, 2021 | 08:10h | UTC
Commentary on Twitter
At 5 years of follow up in CheckMate 017 and 057 trials, nivolumab continues to demonstrate a survival benefit vs docetaxel in patients with previously-treated advanced NSCLC https://t.co/oswZhdAPTW #JCO #lcsm #immunoonc pic.twitter.com/4FZJlfig99
— ASCO Publications (@ASCO_pubs) February 9, 2021
ASCO Guideline: Management of dyspnea in advanced cancer
24 Feb, 2021 | 02:10h | UTCManagement of Dyspnea in Advanced Cancer: ASCO Guideline – Journal of Clinical Oncology
Commentary on Twitter (thread – click for more)
1/ How can we better manage dyspnea in people with advanced cancer?
Wonderful to see this new @ASCO Guideline out.
Led by Drs. @DrDavidHui and @campbell_meg #supponc #pallonc
Full text: https://t.co/qbdhzbibKw pic.twitter.com/f2Qf6GswvK
— Arjun Gupta (@guptaarjun90) February 23, 2021
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
19 Feb, 2021 | 02:04h | UTC
RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%
18 Feb, 2021 | 02:34h | UTC
Commentary on Twitter
Phase 3 trial suggests #cemiplimab could be used as new first-line monotherapy option for patients with advanced non-small-cell #lungcancer with PD-L1 of at least 50%—it improved overall & progression-free survival compared with chemotherapy. Read https://t.co/O06Of6wx07 pic.twitter.com/KtQ24lEoR5
— The Lancet (@TheLancet) February 17, 2021
Radiation therapy for small-cell lung cancer: ASCO Guideline endorsement of an ASTRO Guideline
29 Jan, 2021 | 01:27h | UTC